Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers
Open Access
- 18 March 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (4)
- https://doi.org/10.1128/aac.02150-19
Abstract
E1224 is a prodrug of ravuconazole (RVZ), an antifungal drug with promising anti- Trypanosoma cruzi activity, the causative organism of Chagas disease (CD). This study was designed to assess the pharmacokinetics (PK) and safety interactions of benznidazole (BNZ), the drug of choice for treatment of CD, and E1224 in healthy volunteers.Funding Information
- UK Aid
- Dutch Ministry of Foreign Affairs
- Starr International
- Médecins Sans Frontières
- Swiss Agency for Development and Cooperation
- Bundesministerium für Bildung und Forschung
This publication has 13 references indexed in Scilit:
- Clinical and pharmacological profile of benznidazole for treatment of Chagas diseaseExpert Review of Clinical Pharmacology, 2018
- Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-AnalysisDrug Safety, 2018
- Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in MiceAntimicrobial Agents and Chemotherapy, 2018
- Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trialThe Lancet Infectious Diseases, 2018
- Chagas diseaseThe Lancet, 2017
- Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical TrialsAntimicrobial Agents and Chemotherapy, 2017
- Old and new challenges in Chagas diseaseThe Lancet Infectious Diseases, 2015
- Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' DiseaseThe New England Journal of Medicine, 2014
- Safety of benznidazole use in the treatment of chronic Chagas' diseaseJournal of Antimicrobial Chemotherapy, 2012
- In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas diseaseInternational Journal of Antimicrobial Agents, 2003